| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; loading ...; fig s1c
| Morrissey M, Byrne R, Nulty C, McCabe N, Lynam Lennon N, Butler C, et al. The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation. BMC Cancer. 2020;20:566 pubmed publisher |
- flow cytometry; human; loading ...; fig 4e
| Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher |
- flow cytometry; human; loading ...; fig 5b, 5d, e4f
| Mendoza J, Escalante N, Jude K, Sotolongo Bellon J, Su L, Horton T, et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 2019;567:56-60 pubmed publisher |
- flow cytometry; human; 1:300; loading ...; fig s1b
| Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4: pubmed publisher |
- flow cytometry; human; loading ...; fig 1c
| Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed publisher |
- flow cytometry; human; loading ...; fig s5a
| Jung I, Kim Y, Yu H, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 2018;78:4692-4703 pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...; fig s1a
| Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher |
- immunohistochemistry - frozen section; human; 1:200; fig 5d
| Watanabe R, Shirai T, Namkoong H, Zhang H, Berry G, Wallis B, et al. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest. 2017;127:2725-2738 pubmed publisher |
- blocking or activating experiments; human; loading ...; fig 6c
| Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher |
- mass cytometry; human; fig s8
| Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed publisher |
- flow cytometry; human; fig s4b
| Martin Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb K, et al. Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth. JCI Insight. 2017;2:e89574 pubmed publisher |
- flow cytometry; human; 1:100; fig 5a
| Beatson R, Tajadura Ortega V, Achkova D, Picco G, Tsourouktsoglou T, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273-1281 pubmed publisher |
- flow cytometry; human; fig 4
| Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher |
- flow cytometry; human; loading ...; fig s1
| Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher |
- flow cytometry; human; fig s6b
| Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher |
- flow cytometry; human; 1:200; fig 2
| Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher |
- blocking or activating experiments; human
- flow cytometry; human; fig 7
| Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher |
- flow cytometry; human; fig 6
| Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher |
- flow cytometry; human; loading ...; fig 1
| Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher |
- flow cytometry; human; fig 2
| Du Z, Abedalthagafi M, Aizer A, McHenry A, Sun H, Bray M, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6:4704-16 pubmed |
- flow cytometry; human; fig 4
| Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51 pubmed publisher |
| Zhang G, Lan B, Zhang X, Lin M, Liu Y, Chen J, et al. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells. J Immunother Cancer. 2023;11: pubmed publisher |
| Qiao J, Liu J, Jacobson J, Clark R, Lee S, Liu L, et al. Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma. PLoS ONE. 2022;17:e0277956 pubmed publisher |
| Niu Q, Gao J, Zhao K, Chen X, Lin X, Huang C, et al. Fluid nanoporous microinterface enables multiscale-enhanced affinity interaction for tumor-derived extracellular vesicle detection. Proc Natl Acad Sci U S A. 2022;119:e2213236119 pubmed publisher |
| Perdigoto A, Deng S, Du K, Kuchroo M, Burkhardt D, Tong A, et al. Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes. JCI Insight. 2022;7: pubmed publisher |
| Yonemitsu K, Pan C, Fujiwara Y, Miyasato Y, Shiota T, Yano H, et al. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer. Sci Rep. 2022;12:12007 pubmed publisher |
| Paterson K, Paterson S, Mulholland T, Coffelt S, Zagnoni M. Assessment of CAR-T Cell-Mediated Cytotoxicity in 3D Microfluidic Cancer Co-Culture Models for Combination Therapy. IEEE Open J Eng Med Biol. 2022;3:86-95 pubmed publisher |
| McCarthy E, Odorizzi P, Lutz E, Smullin C, Tenvooren I, Stone M, et al. A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. Cell Rep. 2022;39:110815 pubmed publisher |
| Saber M. Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma. Antibodies (Basel). 2022;11: pubmed publisher |
| Bouchard G, Garcia Marques F, Karacosta L, Zhang W, Bermudez A, Riley N, et al. Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4-pRB Axis in Fibroblasts at the Invasive Tumor Edge. Cancer Res. 2022;82:648-664 pubmed publisher |
| Alpert A, Nahman O, Starosvetsky E, Hayun M, Curiel T, Ofran Y, et al. Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. Cell Syst. 2022;13:71-82.e8 pubmed publisher |
| Kiritsy M, McCann K, MOTT D, Holland S, Behar S, Sassetti C, et al. Mitochondrial respiration contributes to the interferon gamma response in antigen-presenting cells. elife. 2021;10: pubmed publisher |
| Heesters B, van Megesen K, Tomris I, de Vries R, Magri G, Spits H. Characterization of human FDCs reveals regulation of T cells and antigen presentation to B cells. J Exp Med. 2021;218: pubmed publisher |
| Schwabenland M, Salié H, Tanevski J, Killmer S, Lago M, Schlaak A, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021;54:1594-1610.e11 pubmed publisher |
| Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R, et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021;6:236 pubmed publisher |
| Zeller A, Selle M, Gong Z, Winkelmann M, Krettek C, Bundkirchen K, et al. Osteoporosis is accompanied by reduced CD274 expression in human bone marrow-derived mesenchymal stem cells. Eur Cell Mater. 2021;41:603-615 pubmed publisher |
| Garcia de Moura R, Covre L, Fantecelle C, Gajardo V, Cunha C, Stringari L, et al. PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis. Front Immunol. 2021;12:632667 pubmed publisher |
| Zhang D, Reyes R, Osta E, Kari S, Gupta H, Padrón A, et al. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med. 2021;10:2137-2152 pubmed publisher |
| Ma T, Hu C, Lal B, Zhou W, Ma Y, Ying M, et al. Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells. Cancer Res. 2021;81:2457-2469 pubmed publisher |
| Kennedy Darling J, Bhate S, Hickey J, Black S, Barlow G, Vazquez G, et al. Highly multiplexed tissue imaging using repeated oligonucleotide exchange reaction. Eur J Immunol. 2021;51:1262-1277 pubmed publisher |
| Hwang H, Lee J, Kang S, Suh J, Choi E, Jang S, et al. The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells. Immun Inflamm Dis. 2021;9:274-287 pubmed publisher |
| Hang Q, Ying H, Cheng G, Yang S, Jin J, Chen Y, et al. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment]. Zhongguo Fei Ai Za Zhi. 2020;23:837-844 pubmed publisher |
| Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher |
| Zhou B, Yan J, Guo L, Zhang B, Liu S, Yu M, et al. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Theranostics. 2020;10:6530-6543 pubmed publisher |
| Parackova Z, Vrabcová P, Zentsova I, Kayserova J, Richtrova I, Sojka L, et al. Enhanced STAT3 phosphorylation and PD-L1 expression in myeloid dendritic cells indicate impaired IL-27Ralpha signaling in type 1 diabetes. Sci Rep. 2020;10:493 pubmed publisher |
| Merola J, Reschke M, Pierce R, Qin L, Spindler S, Baltazar T, et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression. JCI Insight. 2019;4: pubmed publisher |
| Thiem A, Hesbacher S, Kneitz H, di Primio T, Heppt M, Hermanns H, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38:397 pubmed publisher |
| Kim D, Kim H, Choi Y, Kim S, Lee J, Sung K, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019;51:94 pubmed publisher |
| Baruah P, Bullenkamp J, Wilson P, Lee M, Kaski J, Dumitriu I. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. Front Immunol. 2019;10:1644 pubmed publisher |
| Acheampong E, Spencer I, Lin W, Ziman M, Millward M, Gray E. Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers (Basel). 2019;11: pubmed publisher |
| Salvany Celades M, van der Zwan A, Benner M, Setrajcic Dragos V, Bougleux Gomes H, Iyer V, et al. Three Types of Functional Regulatory T Cells Control T Cell Responses at the Human Maternal-Fetal Interface. Cell Rep. 2019;27:2537-2547.e5 pubmed publisher |
| Enyindah Asonye G, Nwankwo A, Hogge C, Rahman M, Helmold Hait S, Hunegnaw R, et al. A Pathogenic Role for Splenic B1 Cells in SIV Disease Progression in Rhesus Macaques. Front Immunol. 2019;10:511 pubmed publisher |
| Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;: pubmed publisher |
| Sueyoshi K, Ledderose C, Shen Y, Lee A, Shapiro N, Junger W. Lipopolysaccharide suppresses T cells by generating extracellular ATP that impairs their mitochondrial function via P2Y11 receptors. J Biol Chem. 2019;294:6283-6293 pubmed publisher |
| Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019;: pubmed publisher |
| Wang Y, Kim T, Fouladdel S, Zhang Z, Soni P, Qin A, et al. PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer. Sci Rep. 2019;9:566 pubmed publisher |
| Komohara Y, Noyori O, Saito Y, Takeya H, Baghdadi M, Kitagawa F, et al. Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma. J Clin Exp Hematop. 2018;58:152-160 pubmed publisher |
| Agrawal N, Streaţă I, Pei G, Weiner J, Kotze L, Bandermann S, et al. Human Monocytic Suppressive Cells Promote Replication of Mycobacterium tuberculosis and Alter Stability of in vitro Generated Granulomas. Front Immunol. 2018;9:2417 pubmed publisher |
| Ahmed A, Adiga V, Nayak S, Uday Kumar J, Dhar C, Sahoo P, et al. Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis. PLoS Pathog. 2018;14:e1007289 pubmed publisher |
| Hartley G, Chow L, Ammons D, Wheat W, Dow S. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation. Cancer Immunol Res. 2018;6:1260-1273 pubmed publisher |
| Wang B, Zuo J, Kang W, Wei Q, Li J, Wang C, et al. Generation of Hutat2:Fc Knockin Primary Human Monocytes Using CRISPR/Cas9. Mol Ther Nucleic Acids. 2018;11:130-141 pubmed publisher |
| Chaganty B, Qiu S, Gest A, Lu Y, Ivan C, Calin G, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion. Cancer Lett. 2018;430:47-56 pubmed publisher |
| Tang D, Zhao D, Wu Y, Yao R, Zhou L, Lu L, et al. The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med. 2018;: pubmed publisher |
| Wilson J, Zhao Y, Singer M, Spencer J, Shankar Hari M. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. Crit Care. 2018;22:95 pubmed publisher |
| Lee S, Adriani G, Ceccarello E, Pavesi A, Tan A, Bertoletti A, et al. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. Front Immunol. 2018;9:416 pubmed publisher |
| Yamada S, Itai S, Kaneko M, Kato Y. Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4. Biochem Biophys Rep. 2018;13:123-128 pubmed publisher |
| Hsu D, Breglio K, Pei L, Wong C, Andrade B, Sheikh V, et al. Emergence of Polyfunctional Cytotoxic CD4+ T Cells in Mycobacterium avium Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients. Clin Infect Dis. 2018;67:437-446 pubmed publisher |
| Liu R, Merola J, Manes T, Qin L, Tietjen G, Lopez Giraldez F, et al. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1. JCI Insight. 2018;3: pubmed publisher |
| Kim M, Kim C, Kim S, Shin S, Choe E, Park S, et al. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol Res. 2018;: pubmed publisher |
| Janse van Rensburg H, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, et al. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. Cancer Res. 2018;78:1457-1470 pubmed publisher |
| Juttukonda L, Berends E, Zackular J, Moore J, Stier M, Zhang Y, et al. Dietary Manganese Promotes Staphylococcal Infection of the Heart. Cell Host Microbe. 2017;22:531-542.e8 pubmed publisher |
| Horn L, Ciavattone N, Atkinson R, Woldergerima N, Wolf J, Clements V, et al. CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget. 2017;8:57964-57980 pubmed publisher |
| Salio M, Gasser O, González López C, Martens A, Veerapen N, Gileadi U, et al. Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. J Immunol. 2017;199:2631-2638 pubmed publisher |
| Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher |
| Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker J, et al. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. J Immunol. 2017;199:604-612 pubmed publisher |
| Nolan E, Savas P, Policheni A, Darcy P, Vaillant F, Mintoff C, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9: pubmed publisher |
| Lavin Y, Kobayashi S, Leader A, Amir E, Elefant N, Bigenwald C, et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017;169:750-765.e17 pubmed publisher |
| Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed publisher |
| Li C, Lim S, Xia W, Lee H, Chan L, Kuo C, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632 pubmed publisher |
| Daley D, Zambirinis C, Seifert L, Akkad N, Mohan N, Werba G, et al. ?? T Cells Support Pancreatic Oncogenesis by Restraining ?? T Cell Activation. Cell. 2016;166:1485-1499.e15 pubmed publisher |
| Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015;112:E6506-14 pubmed publisher |
| Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015;33:4015-22 pubmed publisher |
| Chang Z, Silver P, Chen Y. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. J Transl Med. 2015;13:161 pubmed publisher |
| Barsoum I, Smallwood C, Siemens D, Graham C. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665-74 pubmed publisher |
